Accessibility Menu
Scinai Immunotherapeutics logo

Scinai Immunotherapeutics(NASDAQ) SCNI

Market Cap$910.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-100%
5 Year-100%
1 Year-89%
1 Month-16%
$0.25
+7.3%
+0.02Today
Scinai Immunotherapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.232026-07-24
Scinai Immunotherapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.93%USD 0.252026-07-17
1 month-15.5%USD 0.272026-06-24
3 month-68.79%USD 0.742026-04-24
Year to date-67.7%USD 0.712025-12-31
1 year-89.25%USD 2.142025-07-24
3 year-98.27%USD 13.302023-07-25
5 year-99.92%USD 286.002021-07-23
Since inception-99.94%USD 399.002015-05-12

Scinai Immunotherapeutics Financials at a Glance

Market Cap

$910.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.42M

Net Income (TTM)

-$2.67M

EPS (TTM)

-$6.15

P/E Ratio

-0.04

Dividend

$0.00

Beta (Volatility)

1.00 (Low)

Price

$0.25

Volume

69,249.628

Open

$0.23

Previous Close

$0.25

Daily Range

$0.23 - $0.28

52-Week Range

$0.21 - $3.48

Estimated Earnings Date

Jul 7, 2026

SCNI News

GettyImages-459898185

Why BiondVax Pharmaceuticals Stock Imploded Today

Prosper Junior BakinyOct 23, 2020

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Scinai Immunotherapeutics

BiondVax Pharmaceuticals Ltd. is an Israeli biopharmaceutical company focused on developing innovative therapeutic products for infectious diseases and other medical conditions. The company is advancing its proprietary nanosized antibodies (NanoAbs) technology through strategic collaborations with leading scientific institutions.

Products and Services
  • Development of nanosized antibodies for various medical conditions
  • COVID-19 therapeutic candidate in advanced stages
  • Collaborative research with Max Planck Society and University Medical Center Göttingen
Growth Outlook
  • Strong pipeline with potential for multiple therapeutic applications
  • Recent partnerships enhance research capabilities and market reach
  • Focus on expanding product offerings in the biopharmaceutical sector
Financial Highlights
  • Q2 2023 net income of -$3.76 million, reflecting ongoing R&D investments
  • Cash and cash equivalents of $7.51 million as of June 30, 2023
  • Current ratio of 6.15 indicates strong liquidity position
BiondVax Pharmaceuticals Ltd. operates in a dynamic biotechnology sector, leveraging its innovative NanoAbs technology to address significant health challenges. The company's strategic partnerships with renowned institutions position it well for future growth and development. Despite recent financial losses, the substantial cash reserves and high current ratio suggest a solid foundation for ongoing research and operational activities. Investors may find BiondVax's focus on cutting-edge therapeutic solutions and its commitment to advancing healthcare particularly compelling.
AI Generated • Jun 28, 2026

Industry

Biotechnology

Sector

Health Care

Employees

45

CEO

Amir Reichman, MBA

Website

www.scinai.com

Headquarters

Jerusalem, JM 9112001, IL

SCNI Financials

Key Financial Metrics (TTM)

Gross Margin

-221.32%

Operating Margin

-573.87%

Net Income Margin

-188.87%

Return on Equity

-29.84%

Return on Capital

-72.73%

Return on Assets

-15.20%

Earnings Yield

-25.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$910.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.96M

Volume

69.25K

Avg. Volume

471.93K

Financials (TTM)

Gross Profit

-$3.13M

Operating Income

-$8.12M

EBITDA

-$7.69M

Operating Cash Flow

-$6.44M

Capital Expenditure

-$18.00K

Free Cash Flow

-$6.46M

Cash & ST Invst.

$3.11M

Total Debt

$3.50M

Scinai Immunotherapeutics Performance Analysis

Scinai Immunotherapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 661,123N/A
20252025-12-31USD 1,321,40099.9%
Scinai Immunotherapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30-28.3%
Q42025-12-31-4.9%
Q12026-03-3185.0%
Scinai Immunotherapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -30.64-65.1%
20232023-12-31USD -16.60-45.8%
20242024-12-31USD 5.99N/A
20252025-12-31USD -3.59N/A
Scinai Immunotherapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-3166.7%
Q12026-03-31960100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$487.67K

+26.2%

Gross Profit

-$1.11M

-75.6%

Gross Margin

-2.29%

N/A

Market Cap

$910.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$20.24K

N/A

Employees

45

N/A

Net Income

$3.57M

+272.6%

EBITDA

-$2.01M

-138.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$3.11M

+214.9%

Total Debt

$3.50M

+48.4%

Accounts Receivable

$150.00K

+7.9%

Inventory

$0.00

N/A

Long Term Debt

$3.14M

+69.0%

Short Term Debt

$354.00K

-28.8%

Return on Assets

-15.20%

N/A

Return on Invested Capital

-54.49%

N/A

Free Cash Flow

-$1.46M

-38.6%

Operating Cash Flow

-$1.45M

-39.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ENVBEnveric Biosciences, Inc.
$1.34+3.88%
SLXNSilexion Therapeutics Ltd.
$2.53+11.45%
SPRCSciSparc Ltd.
$5.01-6.00%
ONCOOnconetix, Inc.
$0.81-0.89%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About SCNI

What is the current price of Scinai Immunotherapeutics?

Scinai Immunotherapeutics is trading at $0.25 per share.

What is the 52-week range for Scinai Immunotherapeutics?

Over the past 52 weeks, Scinai Immunotherapeutics has traded between $0.21 and $3.48.

How much debt does Scinai Immunotherapeutics have?

As of the most recent reporting period, Scinai Immunotherapeutics reported total debt of $3.50M.

How much cash does Scinai Immunotherapeutics have on hand?

Scinai Immunotherapeutics reported $3.11M in cash and cash equivalents in its most recent financial results.

What is Scinai Immunotherapeutics’s dividend yield?

Scinai Immunotherapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services